You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 13, 2024

~ Buy the RHOPRESSA (netarsudil mesylate) Drug Profile, 2024 PDF Report in the Report Store ~

RHOPRESSA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Rhopressa patents expire, and what generic alternatives are available?

Rhopressa is a drug marketed by Alcon Labs Inc and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-eight patent family members in fourteen countries.

The generic ingredient in RHOPRESSA is netarsudil mesylate. One supplier is listed for this compound. Additional details are available on the netarsudil mesylate profile page.

DrugPatentWatch® Generic Entry Outlook for Rhopressa

Rhopressa was eligible for patent challenges on December 18, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for RHOPRESSA
Drug Prices for RHOPRESSA

See drug prices for RHOPRESSA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RHOPRESSA
Generic Entry Date for RHOPRESSA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RHOPRESSA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wills EyePhase 2/Phase 3
Salus UniversityPhase 4
Cornea Research Foundation of AmericaPhase 2/Phase 3

See all RHOPRESSA clinical trials

Pharmacology for RHOPRESSA
Drug ClassRho Kinase Inhibitor
Mechanism of ActionRho Kinase Inhibitors
Paragraph IV (Patent) Challenges for RHOPRESSA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RHOPRESSA Ophthalmic Solution netarsudil mesylate 0.02% 208254 2 2021-12-20

US Patents and Regulatory Information for RHOPRESSA

RHOPRESSA is protected by fourteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of RHOPRESSA is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting RHOPRESSA

Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Combination therapy
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Compositions for treating glaucoma or reducing intraocular pressure
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Combination therapy
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Combination therapy
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Labs Inc RHOPRESSA netarsudil mesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Alcon Labs Inc RHOPRESSA netarsudil mesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Alcon Labs Inc RHOPRESSA netarsudil mesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Alcon Labs Inc RHOPRESSA netarsudil mesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for RHOPRESSA

When does loss-of-exclusivity occur for RHOPRESSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 14228790
Estimated Expiration: ⤷  Try a Trial

Patent: 18202965
Estimated Expiration: ⤷  Try a Trial

Patent: 18202990
Estimated Expiration: ⤷  Try a Trial

Patent: 20203976
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 05089
Estimated Expiration: ⤷  Try a Trial

China

Patent: 5263494
Estimated Expiration: ⤷  Try a Trial

Patent: 9528721
Estimated Expiration: ⤷  Try a Trial

Patent: 0396085
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 11943
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 76080
Estimated Expiration: ⤷  Try a Trial

Patent: 61484
Estimated Expiration: ⤷  Try a Trial

Patent: 11943
Estimated Expiration: ⤷  Try a Trial

Patent: 18759
Estimated Expiration: ⤷  Try a Trial

Finland

Patent: 11943
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 61618
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 16515520
Estimated Expiration: ⤷  Try a Trial

Patent: 19094339
Estimated Expiration: ⤷  Try a Trial

Patent: 20125355
Estimated Expiration: ⤷  Try a Trial

Patent: 20143163
Estimated Expiration: ⤷  Try a Trial

Patent: 21046439
Estimated Expiration: ⤷  Try a Trial

Patent: 23030072
Estimated Expiration: ⤷  Try a Trial

Netherlands

Patent: 1101
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 11943
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 11943
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 76199
Estimated Expiration: ⤷  Try a Trial

Patent: 52377
Estimated Expiration: ⤷  Try a Trial

Patent: 42898
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RHOPRESSA around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 3461484 TRAITEMENT COMBINÉ (COMBINATION THERAPY) ⤷  Try a Trial
Spain 2474150 ⤷  Try a Trial
European Patent Office 4218759 TRAITMENT COMBINÉ (COMBINATION THERAPY) ⤷  Try a Trial
European Patent Office 2424842 INHIBITEURS À MÉCANISME DOUBLE POUR LE TRAITEMENT DE MALADIE (DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for RHOPRESSA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3053913 C202030018 Spain ⤷  Try a Trial PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREOMERO, SAL O SOLVATO DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/19/1400; DATE OF AUTHORISATION: 20191119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1400; DATE OF FIRST AUTHORISATION IN EEA: 20191119
3461484 SPC/GB21/033 United Kingdom ⤷  Try a Trial PRODUCT NAME: A COMBINATION OF LATANOPROST AND NETARSUDIL; REGISTERED: UK EU/1/20/1502(FOR NI) 20210107; UK PLGB 16053/0034 20210107
3461484 2021C/515 Belgium ⤷  Try a Trial PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108
3461484 21C1024 France ⤷  Try a Trial PRODUCT NAME: ASSOCIATION DE NETARSUDIL OU L'UN DE SES SELS ET DE LATANOPROST; REGISTRATION NO/DATE: EU/1/20/1502 20210108
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.